Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia

British Journal of Clinical Pharmacology

Volumn 45, Issue 3, 1998, Pages 265-269

  Vazquez M ^a   Zambon D ^b   Hernandez Y ^a   Adzet, T ^a   Merlos, M ^a   Ros, E ^b   Laguna, J C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Combined hyperlipidaemia; Fatty acids; Gemfibrozil; LDL oxidation; Lovastatin

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN B; ASCORBIC ACID; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET; DOUBLE BLIND PROCEDURE; FAMILIAL HYPERLIPEMIA; FEMALE; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID COMPOSITION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031892547     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00672.x     Document Type: Article

References (24)

1. Tribble DL. Lipoprotein oxidation in dyslipidemia: insights into general mechanisms affecting lipoprotein oxidative behavior. Curr Opin Lipidol 1995; 6: 196-208.
2. Bonanome A, Pagnan A, Biffanti S, et al. Effect of dietary monounsaturated and polyunsaturated fatty acids on the susceptibility of plasma low density lipoproteins to oxidative modification. Arterioscler Thromb 1992; 12: 529-533.
3. Scaccini C, Nardini M, D'Aquino M, Gentili V, Di Felice M, Tomassi G. Effect of dietary oils on lipid peroxidation and on antioxidants parameters of rat plasma and lipoprotein fractions. J Lipid Res 1992; 33: 627-633.
4. Aviram M, Danker G, Cogan U, Hochgraf E, Brook JG. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 1992; 41: 229-235.
5. de Graaf, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment. Arterioscler Thromb 1993; 13: 712-719.
6. Agheli N, Jacotot B. Effect of simvastatin and fenofibrate on the fatty acid composition of hypertriglyceridemic patients. Br J Clin Pharmacol 1991; 32: 423-428.
7. Zambón D, Villar CR, Sanllehy C, Canals E, Ros E. Comparative study of gemfibrozil (GF) and lovastatin (LV) in combined hyperlipidemia (CHL). XII International Symposium of Drugs Affecting Lipid Metabolism, Houston, TX, USA, 1995, Abstracts Book pp 127.
8. Vázquez M, Merlos M, Adzet T, Laguna JC. Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment. Influence of fatty acid composition. Br J Pharmacol 1996; 117: 1155-1162.
9. Bradford M. A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal Biochem 1976; 72: 248-254.
10. Vázquez M, Muñoz S, Alegret M, Adzet T, Merlos M, Laguna JC. Fibrates show differential effects on the acyl composition of microsomal phospholipids in rats. Br J Pharmacol 1995; 116: 2067-2075.
11. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983; 24: 147-156.
12. Eisenberg S, Gavish D, Oschry Y, Fainaru M, Deckelbaum RJ. Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. J Clin Invest 1984; 74: 470-482.
13. Austin MA, King M-C, Vranigan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506.
14. Henwood JM, Heel RC. Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 1988; 36: 429-454.
15. Todd PA, Ward A. Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs 1988; 36: 314-339.
16. Ojala J-P, Helve E, Tikkanen MJ. Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: A comparison study. Cardiology 1990; 77: 39-49.
17. Vega GL, Grundy SM. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy. JAMA 1990; 264: 2759-2763.
18. Tikkanen MJ, Ojala J-P, Helve E. Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia. Eur J Clin Pharmacol 1991; 40: S23-S25.
19. Shepherd J, Griffin B, Caslake M, Gaw A, Packard. The influence of fibrates on lipoprotein metabolism. Atherosclerosis Rev 1991; 22: 163-169.
20. Agheli N, Jacotot B, Ayrault-Jarrier M, Lemonnier D. Compositions of serum lipids, lipoproteins, and lipoprotein fatty acids in Type IV primary hypertriglyceridemia. J Clin Biochem Nutr 1992; 12: 131-140.
21. Ruíz-Guitiérrez V, Prada JL, Pérez-Jiménez F. Determination of fatty acid and triacylglycerol composition of human very-low-density lipoproteins. J Chromatogr 1993; 622: 117-124.
22. Cinti DL, Cook L, Nagi MN, Suneja SK. The fatty acid chain elongation system of mammalian endoplasmic reticulum. Prog Lipid Res 1992; 31: 1-51.
23. Huang Y-S, Manku MS, Horrobin DF. The effects of dietary cholesterol on blood liver polyunsaturated fatty acids and on plasma cholesterol in rats fed various types of fatty acid diet. Lipids 1984; 19: 664-672.
24. Bredie SJH, de Bruin TWA, Demacker PNM, Kastalein JJP, Stalenhoef AFH. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containmg lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 1995; 75: 348-353.